Trials / Completed
CompletedNCT00304447
Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia
A Phase IV Study of Corticosteroids As Prophylaxis for Infusion-Related Adverse Events to Mylotarg® in Patients With Acute Myelogenous Leukemia (AML)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of corticosteroids on the frequency and severity of Mylotarg® infusion-related adverse events, to evaluate the effect of corticosteroids on the efficacy of Mylotarg® induced complete response (CR) and complete response with incomplete platelet recovery (CRp) at one-month post treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mylotarg |
Timeline
- Start date
- 2002-04-01
- Completion
- 2004-01-01
- First posted
- 2006-03-17
- Last updated
- 2009-07-29
Source: ClinicalTrials.gov record NCT00304447. Inclusion in this directory is not an endorsement.